Published in Eur J Cancer on July 23, 2010
Metformin Pharmacology in Human Cancers: A Proof of Principle Study | NCT03477162
Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond) (2012) 4.04
Serine, glycine and one-carbon units: cancer metabolism in full circle. Nat Rev Cancer (2013) 3.23
Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS One (2012) 2.84
Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality. Eur Urol (2012) 2.45
Anticancer targets in the glycolytic metabolism of tumors: a comprehensive review. Front Pharmacol (2011) 2.24
Metabolic regulation by p53 family members. Cell Metab (2013) 2.00
Metformin: multi-faceted protection against cancer. Oncotarget (2011) 2.00
Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis. Oncologist (2012) 1.79
Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: results from a large population-based follow-up study. Diabetes Care (2011) 1.52
Understanding obesity and endometrial cancer risk: opportunities for prevention. Am J Obstet Gynecol (2011) 1.42
Associations between time spent sitting and cancer-related biomarkers in postmenopausal women: an exploration of effect modifiers. Cancer Causes Control (2014) 1.37
Metabolomic fingerprint reveals that metformin impairs one-carbon metabolism in a manner similar to the antifolate class of chemotherapy drugs. Aging (Albany NY) (2012) 1.31
AMPKα modulation in cancer progression: multilayer integrative analysis of the whole transcriptome in Asian gastric cancer. Cancer Res (2012) 1.31
Validating drug repurposing signals using electronic health records: a case study of metformin associated with reduced cancer mortality. J Am Med Inform Assoc (2014) 1.25
Diabetes and cancer: two diseases with obesity as a common risk factor. Diabetes Obes Metab (2013) 1.11
Metabolism and brain cancer. Clinics (Sao Paulo) (2011) 1.10
Metformin, a diabetes drug, eliminates tumor-initiating hepatocellular carcinoma cells. PLoS One (2013) 1.06
AMPK reverses the mesenchymal phenotype of cancer cells by targeting the Akt-MDM2-Foxo3a signaling axis. Cancer Res (2014) 1.04
Direct inhibition of hexokinase activity by metformin at least partially impairs glucose metabolism and tumor growth in experimental breast cancer. Cell Cycle (2013) 1.03
Latest insights into the risk of cancer in diabetes. J Diabetes Investig (2013) 1.01
Dietary restriction-resistant human tumors harboring the PIK3CA-activating mutation H1047R are sensitive to metformin. Oncotarget (2013) 1.01
Genome protective effect of metformin as revealed by reduced level of constitutive DNA damage signaling. Aging (Albany NY) (2011) 1.01
Repositioning chloroquine and metformin to eliminate cancer stem cell traits in pre-malignant lesions. Drug Resist Updat (2011) 1.01
Adipocytes: impact on tumor growth and potential sites for therapeutic intervention. Pharmacol Ther (2013) 1.00
Paradoxic effects of metformin on endothelial cells and angiogenesis. Carcinogenesis (2014) 1.00
Glycolytic rate and lymphomagenesis depend on PARP14, an ADP ribosyltransferase of the B aggressive lymphoma (BAL) family. Proc Natl Acad Sci U S A (2011) 0.99
Pharmacological manipulation of the cell cycle and metabolism to protect normal tissues against conventional anticancer drugs. Oncotarget (2011) 0.98
Metformin use and improved response to therapy in rectal cancer. Cancer Med (2013) 0.97
Lessons from mouse models of high-fat diet-induced NAFLD. Int J Mol Sci (2013) 0.97
Metformin impairs the growth of liver kinase B1-intact cervical cancer cells. Gynecol Oncol (2012) 0.97
AMPK/mTOR-mediated inhibition of survivin partly contributes to metformin-induced apoptosis in human gastric cancer cell. Cancer Biol Ther (2015) 0.96
Metformin in non-diabetic patients presenting with ST elevation myocardial infarction: rationale and design of the glycometabolic intervention as adjunct to primary percutaneous intervention in ST elevation myocardial infarction (GIPS)-III trial. Cardiovasc Drugs Ther (2012) 0.94
A phase I study of temsirolimus and metformin in advanced solid tumours. Invest New Drugs (2010) 0.93
Association of cancer metabolism-related proteins with oral carcinogenesis - indications for chemoprevention and metabolic sensitizing of oral squamous cell carcinoma? J Transl Med (2014) 0.92
Diabetes, pancreatic cancer, and metformin therapy. Front Physiol (2014) 0.92
Hyperglycemia enhances the proliferation of non-tumorigenic and malignant mammary epithelial cells through increased leptin/IGF1R signaling and activation of AKT/mTOR. PLoS One (2013) 0.90
Anti-angiogenic Effects of Metformin, an AMPK Activator, on Human Umbilical Vein Endothelial Cells and on Granulation Tissue in Rat. Iran J Basic Med Sci (2012) 0.90
Targeted inhibition of BRAF kinase: opportunities and challenges for therapeutics in melanoma. Biosci Rep (2012) 0.90
p53 as an intervention target for cancer and aging. Pathobiol Aging Age Relat Dis (2013) 0.89
Metformin Increases Sensitivity of Pancreatic Cancer Cells to Gemcitabine by Reducing CD133(+) Cell Populations and Suppressing ERK/P70S6K Signaling. Sci Rep (2015) 0.89
Metformin--an adjunct antineoplastic therapy--divergently modulates tumor metabolism and proliferation, interfering with early response prediction by 18F-FDG PET imaging. J Nucl Med (2013) 0.89
Control of Glycolytic Flux by AMP-Activated Protein Kinase in Tumor Cells Adapted to Low pH. Transl Oncol (2012) 0.89
Addition of insulin glargine or NPH insulin to metformin monotherapy in poorly controlled type 2 diabetic patients decreases IGF-I bioactivity similarly. Diabetologia (2012) 0.88
Can the therapeutic effects of temozolomide be potentiated by stimulating AMP-activated protein kinase with olanzepine and metformin? Br J Pharmacol (2011) 0.88
Recent advances in the use of metformin: can treating diabetes prevent breast cancer? Biomed Res Int (2015) 0.87
Targeting the LKB1 tumor suppressor. Curr Drug Targets (2014) 0.87
Catch it before it kills: progesterone, obesity, and the prevention of endometrial cancer. Discov Med (2012) 0.87
The metabolic and mitogenic properties of basal insulin analogues. Arch Physiol Biochem (2013) 0.86
Long-term use of metformin and colorectal cancer risk in type II diabetics: a population-based case-control study. Cancer Med (2014) 0.85
Long-term use of metformin and the molecular subtype in invasive breast carcinoma patients - a retrospective study of clinical and tumor characteristics. BMC Cancer (2014) 0.84
Global gene expression profiling in mouse plasma cell tumor precursor and bystander cells reveals potential intervention targets for plasma cell neoplasia. Blood (2011) 0.84
Metformin for primary colorectal cancer prevention in patients with diabetes: a case-control study in a US population. Cancer (2014) 0.84
Antagonism of sorafenib and regorafenib actions by platelet factors in hepatocellular carcinoma cell lines. BMC Cancer (2014) 0.83
C57BL/KsJ-db/db-Apc mice exhibit an increased incidence of intestinal neoplasms. Int J Mol Sci (2011) 0.83
Metformin inhibits leptin-induced growth and migration of glioblastoma cells. Oncol Lett (2012) 0.83
Type 2 diabetes mellitus, oral diabetic medications, insulin therapy, and overall breast cancer risk. ISRN Endocrinol (2013) 0.83
Simple sugar intake and hepatocellular carcinoma: epidemiological and mechanistic insight. Nutrients (2014) 0.82
Preventing aggressive prostate cancer with proven cardiovascular disease preventive methods. Asian J Androl (2015) 0.81
Anti-tumor activity of metformin: from metabolic and epigenetic perspectives. Oncotarget (2016) 0.81
Activation of AMP-Activated Protein Kinase α and Extracelluar Signal-Regulated Kinase Mediates CB-PIC-Induced Apoptosis in Hypoxic SW620 Colorectal Cancer Cells. Evid Based Complement Alternat Med (2013) 0.81
High efficacy of intravesical treatment of metformin on bladder cancer in preclinical model. Oncotarget (2016) 0.80
Prostate cancer: Diabetes and prostate cancer--an open debate. Nat Rev Urol (2012) 0.79
Metformin against cancer stem cells through the modulation of energy metabolism: special considerations on ovarian cancer. Biomed Res Int (2014) 0.79
Systematic review: Preventive and therapeutic applications of metformin in liver disease. World J Hepatol (2015) 0.79
Insulin-resistant conditions: A favorable milieu for aggressive drug-resistant malignancies. J Gastrointest Oncol (2011) 0.78
Heart healthy equals prostate healthy and statins, aspirin, and/or metformin (S.A.M.) are the ideal recommendations for prostate cancer prevention. Asian J Androl (2015) 0.78
AMPK activation--protean potential for boosting healthspan. Age (Dordr) (2013) 0.78
Association between metformin use and mortality in patients with type 2 diabetes mellitus and localized resectable pancreatic cancer: a nationwide population-based study in korea. Oncotarget (2017) 0.78
Combined Treatment with Exendin-4 and Metformin Attenuates Prostate Cancer Growth. PLoS One (2015) 0.77
Metformin therapy and prostate cancer risk: a meta-analysis of observational studies. Int J Clin Exp Med (2015) 0.77
Changes in [18F]Fluoro-2-deoxy-D-glucose incorporation induced by doxorubicin and anti-HER antibodies by breast cancer cells modulated by co-treatment with metformin and its effects on intracellular signalling. J Cancer Res Clin Oncol (2015) 0.77
Modulation of Regorafenib effects on HCC cell lines by epidermal growth factor. Cancer Chemother Pharmacol (2015) 0.77
Heart healthy=prostate healthy: SELECT, the symbolic end of preventing prostate cancer via heart unhealthy and over anti-oxidation mechanisms? Asian J Androl (2011) 0.77
Effect of metformin on the human T98G glioblastoma multiforme cell line. Exp Ther Med (2014) 0.77
Chemoprevention of Breast Cancer: The Paradox of Evidence versus Advocacy Inaction. Cancers (Basel) (2012) 0.76
Metabolic alterations and increased liver mTOR expression precede the development of autoimmune disease in a murine model of lupus erythematosus. PLoS One (2012) 0.76
Activation of AMP-activated Protein Kinase by Metformin Induces Protein Acetylation in Prostate and Ovarian Cancer Cells. J Biol Chem (2016) 0.76
Systematic Review with Network Meta-Analysis: Antidiabetic Medication and Risk of Hepatocellular Carcinoma. Sci Rep (2016) 0.76
Spontaneous regression of hepatocellular carcinoma in a Caucasian male patient: A case report and review of the literature. Mol Clin Oncol (2016) 0.75
Diabetic concentrations of metformin inhibit platelet-mediated ovarian cancer cell progression. Oncotarget (2017) 0.75
Lactate, a Neglected Factor for Diabetes and Cancer Interaction. Mediators Inflamm (2016) 0.75
A new compartmental method for the analysis of liver FDG kinetics in small animal models. EJNMMI Res (2015) 0.75
Targeting mTOR in Pancreatic Ductal Adenocarcinoma. Front Oncol (2016) 0.75
Switching the sphingolipid rheostat in the treatment of diabetes and cancer comorbidity from a problem to an advantage. Biomed Res Int (2015) 0.75
The effect of metformin treatment in vivo on acute and long-term energy metabolism and progesterone production in vitro by granulosa cells from women with polycystic ovary syndrome. Hum Reprod (2014) 0.75
Drug safety advances from ICPE 2010. Ther Adv Drug Saf (2010) 0.75
In vitro and in vivo targeting of bladder carcinoma with metformin in combination with cisplatin. Oncol Lett (2015) 0.75
Incidence and Mortality Risks of Cancer in Patients with Type 2 Diabetes: A Retrospective Study in Shanghai, China. Int J Environ Res Public Health (2016) 0.75
Anti-tumor effects of everolimus and metformin are complementary and glucose-dependent in breast cancer cells. BMC Cancer (2017) 0.75
Pro-angiogenic Role of Insulin: From Physiology to Pathology. Front Physiol (2017) 0.75
Metformin requires 4E-BPs to induce apoptosis and repress translation of Mcl-1 in hepatocellular carcinoma cells. Oncotarget (2016) 0.75
Addressing the Role of Obesity in Endometrial Cancer Risk, Prevention, and Treatment. J Clin Oncol (2016) 0.75
Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med (2011) 11.55
Evidence based selection of housekeeping genes. PLoS One (2007) 7.90
Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation (2002) 7.25
Physiological approach to assessment of acid-base disturbances. N Engl J Med (2014) 4.50
Acute chemotherapy-induced cardiovascular changes in patients with testicular cancer. J Clin Oncol (2005) 3.29
High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. N Engl J Med (2003) 3.15
Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care (2009) 2.90
High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials. J Clin Oncol (2011) 2.73
Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol (2007) 2.68
Glucose-insulin-potassium infusion inpatients treated with primary angioplasty for acute myocardial infarction: the glucose-insulin-potassium study: a randomized trial. J Am Coll Cardiol (2003) 2.40
A review on CXCR4/CXCL12 axis in oncology: no place to hide. Eur J Cancer (2012) 2.39
Molecular and clinical characteristics of MSH6 variants: an analysis of 25 index carriers of a germline variant. Am J Hum Genet (2002) 2.17
Thyroid function is associated with components of the metabolic syndrome in euthyroid subjects. J Clin Endocrinol Metab (2006) 2.17
Fatigue and relating factors in high-risk breast cancer patients treated with adjuvant standard or high-dose chemotherapy: a longitudinal study. J Clin Oncol (2005) 2.14
Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging. J Nucl Med (2009) 2.12
Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography. J Clin Oncol (2008) 2.03
[Primary surgery by a gynecological oncologist improves the prognosis in patients with ovarian carcinoma]. Ned Tijdschr Geneeskd (2009) 1.97
TRAIL receptor signalling and modulation: Are we on the right TRAIL? Cancer Treat Rev (2008) 1.94
The metabolic syndrome in cancer survivors. Lancet Oncol (2010) 1.93
The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer. J Clin Oncol (2005) 1.88
Survival-related profile, pathways, and transcription factors in ovarian cancer. PLoS Med (2009) 1.88
Bevacizumab-induced normalization of blood vessels in tumors hampers antibody uptake. Cancer Res (2013) 1.87
Receptor conversion in distant breast cancer metastases. Breast Cancer Res (2010) 1.85
Imatinib mesylate for the treatment of gastrointestinal stromal tumours: best monitored with FDG PET. Nucl Med Commun (2004) 1.84
Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients. J Am Soc Nephrol (2005) 1.82
Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study. Lancet Oncol (2006) 1.79
High-grade dysplasia in sporadic fundic gland polyps: a case report and review of the literature. Eur J Gastroenterol Hepatol (2003) 1.77
Risk of new primary nonbreast cancers after breast cancer treatment: a Dutch population-based study. J Clin Oncol (2008) 1.76
Testicular cancer survivorship: research strategies and recommendations. J Natl Cancer Inst (2010) 1.76
Plasma free metanephrine measurement using automated online solid-phase extraction HPLC tandem mass spectrometry. Clin Chem (2007) 1.74
Skin autofluorescence is a strong predictor of cardiac mortality in diabetes. Diabetes Care (2007) 1.73
Variation in bleomycin hydrolase gene is associated with reduced survival after chemotherapy for testicular germ cell cancer. J Clin Oncol (2008) 1.63
Intraoperative near-infrared fluorescence tumor imaging with vascular endothelial growth factor and human epidermal growth factor receptor 2 targeting antibodies. J Nucl Med (2011) 1.62
Feasibility of withholding antibiotics in selected febrile neutropenic cancer patients. J Clin Oncol (2005) 1.62
Cardiovascular toxicity caused by cancer treatment: strategies for early detection. Lancet Oncol (2009) 1.58
The prognostic effect of the number of histologically examined axillary lymph nodes in breast cancer: stage migration or age association? Ann Surg Oncol (2006) 1.58
The insulin-like growth factor system and sarcomas. J Pathol (2009) 1.57
Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol (2006) 1.57
Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma. Cancer (2006) 1.55
Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol (2006) 1.55
Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism. Eur J Clin Pharmacol (2010) 1.55
The relationship between glycaemic control and mortality in patients with type 2 diabetes in general practice (ZODIAC-11). Br J Gen Pract (2010) 1.54
TRAIL induces apoptosis in human colorectal adenoma cell lines and human colorectal adenomas. Clin Cancer Res (2006) 1.52
Low p21Waf1/Cip1 protein level sensitizes testicular germ cell tumor cells to Fas-mediated apoptosis. Oncogene (2004) 1.50
Low-penetrance genes and their involvement in colorectal cancer susceptibility. Cancer Epidemiol Biomarkers Prev (2002) 1.50
Playing the DISC: turning on TRAIL death receptor-mediated apoptosis in cancer. Biochim Biophys Acta (2009) 1.45
Renoprotective effects of long-term oral nicotine in a rat model of spontaneous proteinuria. Am J Physiol Renal Physiol (2012) 1.44
Cytoplasmic p21 expression levels determine cisplatin resistance in human testicular cancer. J Clin Invest (2010) 1.43
Validation of serum amyloid α as an independent biomarker for progression-free and overall survival in metastatic renal cell cancer patients. Eur Urol (2012) 1.41
Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail (2011) 1.40
Chromium treatment has no effect in patients with poorly controlled, insulin-treated type 2 diabetes in an obese Western population: a randomized, double-blind, placebo-controlled trial. Diabetes Care (2006) 1.40
Translating pharmacogenomics: challenges on the road to the clinic. PLoS Med (2007) 1.39
ATP-binding cassette (ABC) transporters in normal and pathological lung. Respir Res (2005) 1.37
Roles of radiation dose and chemotherapy in the etiology of stomach cancer as a second malignancy. Int J Radiat Oncol Biol Phys (2009) 1.36
Toward new strategies to select young endometrial cancer patients for mismatch repair gene mutation analysis. J Clin Oncol (2003) 1.31
Preclinical characterisation of 111In-DTPA-trastuzumab. Br J Pharmacol (2004) 1.31
Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors. Clin Cancer Res (2003) 1.29
Tissue distribution of the death ligand TRAIL and its receptors. J Histochem Cytochem (2004) 1.27
VEGF-PET imaging is a noninvasive biomarker showing differential changes in the tumor during sunitinib treatment. Cancer Res (2010) 1.27
Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up. J Clin Oncol (2012) 1.26
Prognosis in childhood and adult acute lymphoblastic leukaemia: a question of maturation? Cancer Treat Rev (2004) 1.25
Clinical evaluation of M30 and M65 ELISA cell death assays as circulating biomarkers in a drug-sensitive tumor, testicular cancer. Neoplasia (2008) 1.25
Health-related quality of life and mortality in a general and elderly population of patients with type 2 diabetes (ZODIAC-18). Diabetes Care (2010) 1.24
89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922. J Nucl Med (2010) 1.23
ABC transporter expression in hematopoietic stem cells and the role in AML drug resistance. Crit Rev Oncol Hematol (2007) 1.21
The metabolic syndrome in long-term cancer survivors, an important target for secondary preventive measures. Cancer Treat Rev (2002) 1.17
Expression of TRAIL (TNF-related apoptosis-inducing ligand) and its receptors in normal colonic mucosa, adenomas, and carcinomas. J Pathol (2003) 1.17
Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I study. Clin Cancer Res (2009) 1.16
Lipid-soluble components in cigarette smoke induce mitochondrial production of reactive oxygen species in lung epithelial cells. Am J Physiol Lung Cell Mol Physiol (2009) 1.16
Vascular damage in testicular cancer patients: a study on endothelial activation by bleomycin and cisplatin in vitro. Oncol Rep (2010) 1.15
Back to basics in diagnosing diabetic polyneuropathy with the tuning fork! Diabetes Care (2005) 1.15
An oncological view on the blood-testis barrier. Lancet Oncol (2002) 1.15
Involvement of the TGF-beta and beta-catenin pathways in pelvic lymph node metastasis in early-stage cervical cancer. Clin Cancer Res (2011) 1.13
Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy. Drug Resist Updat (2005) 1.13
Effect of vemurafenib on a V600R melanoma brain metastasis. Eur J Cancer (2013) 1.13
Quantitative assessment of P-glycoprotein function in the rat blood-brain barrier by distribution volume of [11C]verapamil measured with PET. Neuroimage (2003) 1.13
6-[F-18]Fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with (123)I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess. J Clin Endocrinol Metab (2009) 1.11
Carotid plaque formation and serum biomarkers. Atherosclerosis (2010) 1.11
Chloride: the queen of electrolytes? Eur J Intern Med (2011) 1.11
PET imaging of oestrogen receptors in patients with breast cancer. Lancet Oncol (2013) 1.10
The impact of adjuvant therapy on contralateral breast cancer risk and the prognostic significance of contralateral breast cancer: a population based study in the Netherlands. Breast Cancer Res Treat (2007) 1.10
Translating TRAIL-receptor targeting agents to the clinic. Cancer Lett (2012) 1.10